The defense ministry said there was too little demand for its Fakhravac vaccine to justify producing it, and blamed the health ministry for reneging on promised orders.
Tag: Drugs (Pharmaceuticals)
Iran Plans to Abandon One of Its Homegrown Covid Shots
The defense ministry said there was too little demand for its Fakhravac vaccine to justify producing it, and blamed the health ministry for reneging on promised orders.
Gates Foundation Pledges $120 Million to Help Get Merck Covid Pills to Poor Countries
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
Asia-Pacific Countries Rush to Buy Merck Covid Pill
The home treatment, molnupiravir, is said by the company to potentially halve the risk of hospitalization and death from the virus.
Pfizer Booster Can Be Given After 6 Months, European Drug Agency Says
The European Medicines Agency also said that extra doses of the Moderna and Pfizer-BioNTech vaccines could be given to people with underlying health conditions as early as 28 days after a second dose.
W.H.O. Backs Antibody Treatment For High-Risk Covid Patients
The expensive treatment, developed by the U.S. drug maker Regeneron and the Swiss biotech company Roche, has garnered attention as backstop for those who shun vaccines.
Pressure Grows on U.S. Companies to Share Covid Vaccine Technology
Moderna accepted $2.5 billion in taxpayer money to develop its Covid-19 vaccine. But officials in the U.S. and overseas are having trouble persuading the company to license its technology.
Study of Covid Booster Shot Benefits Fans Debate Over Extra Doses
Independent experts, including government scientists, were skeptical of the research from Israel, which included limited data over a short period.
Ivermectin Won’t Treat Covid-19, but Demand Is High Anyway
Clinical trials have repeatedly failed to show that the drug is effective against the virus. Still, U.S. demand is high.